Patents Assigned to Halozyme, Inc.
-
Patent number: 11952600Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.Type: GrantFiled: June 20, 2023Date of Patent: April 9, 2024Assignee: Halozyme, Inc.Inventors: Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
-
Publication number: 20240024471Abstract: The disclosure provides pharmaceutical compositions comprising an anti-PD-1 antibody or an anti-PD-L1 antibody. In some aspects, the pharmaceutical compositions are formulated for subcutaneous delivery. In some aspects, the pharmaceutical compositions further comprise an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering a pharmaceutical composition comprising an anti-PD-1 antibody or an anti-PD-L1 antibody.Type: ApplicationFiled: August 21, 2023Publication date: January 25, 2024Applicants: Bristol-Myers Squibb Company, Halozyme, Inc.Inventors: Masano HUANG, Thomas Arthur HABY, Mehrnaz KHOSSRAVI, Scott Aaron HART, Rao Venkatramana MANTRI, Heather Elizabeth VEZINA, Amit ROY, Bindu Purnima MURTHY, Urvi Ashish ARAS, Kinjal SANGHAVI, Xiaochen ZHAO, Akintunde BELLO
-
Publication number: 20240000934Abstract: The disclosure provides pharmaceutical compositions comprising an antibody and at least two antioxidants. In some aspects, pharmaceutical composition is formulated for subcutaneous delivery. In some aspects, the pharmaceutical composition further comprises an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering the pharmaceutical composition.Type: ApplicationFiled: August 21, 2023Publication date: January 4, 2024Applicants: Bristol-Myers Squibb Company, Halozyme, Inc.Inventors: Masano HUANG, Thomas Arthur HABY, Mehrnaz KHOSSRAVI, Scott Aaron HART, Rao Venkatramana MANTRI, Heather Elizabeth VEZINA, Amit ROY, Bindu Purnima MURTHY, Urvi Ashish ARAS, Kinjal SANGHAVI, Xiaochen ZHAO, Akintunde BELLO
-
Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide
Patent number: 11723959Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration for in vitro fertilization, as well as administration of molecules, or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.Type: GrantFiled: October 2, 2020Date of Patent: August 15, 2023Assignee: Halozyme, Inc.Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost -
Patent number: 11584923Abstract: Provided are variant adenosine deaminase 2 (ADA2) proteins, conjugates thereof and compositions containing the proteins and/or conjugates. Also provided are methods and uses of the ADA2 proteins or conjugates for treating diseases and conditions, such as a tumor or cancer, and in particular any disease or condition associated with elevated adenosine or other associated marker.Type: GrantFiled: March 29, 2018Date of Patent: February 21, 2023Assignee: Halozyme, Inc.Inventors: Christopher D. Thanos, Lin Wang, H. Michael Shepard
-
Patent number: 11414489Abstract: Provided are methods of treatments with combinations or compositions containing a soluble hyaluronidase, such as a polymer-modified hyaluronidase, and an immune checkpoint inhibitor treating cancers, including solid and non-solid tumors. The combinations and compositions also are provided.Type: GrantFiled: February 27, 2017Date of Patent: August 16, 2022Assignee: Halozyme, Inc.Inventors: Sanna Rosengren, H. Michael Shepard, Curtis B. Thompson
-
Publication number: 20220233689Abstract: The disclosure provides pharmaceutical compositions comprising an anti-PD-1 antibody or an anti-PD-L1 antibody. In some aspects, the pharmaceutical compositions are formulated for subcutaneous delivery. In some aspects, the pharmaceutical compositions further comprise an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering a pharmaceutical composition comprising an anti-PD-1 antibody or an anti-PD-L1 antibody.Type: ApplicationFiled: December 27, 2021Publication date: July 28, 2022Applicants: Bristol-Myers Squibb Company, Halozyme, Inc.Inventors: Masano Huang, Thomas Arthur Haby, Mehrnaz KHOSSRAVI, Scott Aaron HART, Rao Venkatramana MANTRI, Heather Elizabeth VEZINA, Amit ROY, Bindu Purnima MURTHY, Urvi Ashish ARAS, Kinjal SANGHAVI, Xiaochen ZHAO, Akintunde BELLO
-
Publication number: 20220233693Abstract: The disclosure provides pharmaceutical compositions comprising an antibody and at least two antioxidants. In some aspects, pharmaceutical composition is formulated for subcutaneous delivery. In some aspects, the pharmaceutical composition further comprises an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering the pharmaceutical composition.Type: ApplicationFiled: December 27, 2021Publication date: July 28, 2022Applicants: Bristol-Myers Squibb Company, Halozyme, Inc.Inventors: Masano HUANG, Thomas Arthur HABY, Mehrnaz KHOSSRAVI, Scott Aaron HART, Rao Venkatramana MANTRI, Heather Elizabeth VEZINA, Amit ROY, Bindu Purnima MURTHY, Urvi Ashish ARAS, Kinjal SANGHAVI, Xiaochen ZHAO, Akintunde BELLO
-
Patent number: 11066656Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.Type: GrantFiled: June 25, 2020Date of Patent: July 20, 2021Assignee: Halozyme, Inc.Inventors: Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
-
Patent number: 11041149Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.Type: GrantFiled: March 19, 2020Date of Patent: June 22, 2021Assignee: Halozyme, Inc.Inventors: Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
-
Patent number: 10898551Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.Type: GrantFiled: April 2, 2019Date of Patent: January 26, 2021Assignee: Halozyme, Inc.Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
-
Patent number: 10865400Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.Type: GrantFiled: August 2, 2016Date of Patent: December 15, 2020Assignee: Halozyme, Inc.Inventors: Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
-
Patent number: 10588983Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.Type: GrantFiled: February 23, 2018Date of Patent: March 17, 2020Assignee: Halozyme, Inc.Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
-
Patent number: 10328130Abstract: Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders. In one example, the products include an additional agent or treatment. Such products can be used in methods for administering the products to treat the hyaluronan-associated diseases and conditions, for example, hyaluronan-associated cancers, for example, hyaluronan-rich tumors. The methods include administration of the hyaluronan degrading enzyme composition alone or in combination with other treatments. Also provided are methods and compositions for providing sustained treatment effects in hyaluronan-associated diseases and conditions.Type: GrantFiled: February 22, 2012Date of Patent: June 25, 2019Assignee: Halozyme, Inc.Inventors: Gregory I. Frost, Ping Jiang, Curtis B. Thompson
-
Patent number: 10286044Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.Type: GrantFiled: May 9, 2017Date of Patent: May 14, 2019Assignee: Halozyme, Inc.Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
-
Patent number: 10265410Abstract: Provided herein are methods for ameliorating an adverse effect of systemic administration of a PEG hyaluronan degrading enzyme to a subject. The methods involve systemically administering a PEGylated hyaluronan degrading enzyme, particularly a PEGylated hyaluronidase, such as any of the animal or bacterial hyaluronidases, to the subject and administering an amount of a corticosteroid sufficient to ameliorate the adverse effect. Also provided are method of treating a hyaluronan-associated disease or condition for single-agent therapy or combination therapy.Type: GrantFiled: April 15, 2016Date of Patent: April 23, 2019Assignee: Halozyme, Inc.Inventors: Harold Michael Shepard, Curtis Thompson, Xiaoming Li, Gregory I. Frost
-
Patent number: 10137104Abstract: Provided herein is combination cancer therapy effected by administering a polymer-conjugated hyaluronidase, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.Type: GrantFiled: June 16, 2017Date of Patent: November 27, 2018Assignee: Halozyme, Inc.Inventors: Daniel C. Maneval, H. Michael Shepard, Curtis B. Thompson
-
Patent number: 10016491Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.Type: GrantFiled: November 9, 2015Date of Patent: July 10, 2018Assignee: Halozyme, Inc.Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
-
Patent number: 9993529Abstract: Provided are compositions that are stable formulations of a hyaluronan-degrading enzyme or are stable co-formulations of a fast-acting insulin and a hyaluronan degrading enzyme, including a recombinant human PH20 (rHuPH20).Type: GrantFiled: June 15, 2012Date of Patent: June 12, 2018Assignee: Halozyme, Inc.Inventors: Tzung-Horng Yang, Daniel Edward Vaughn, Michael James Labarre, Christopher L. Caster, Francois Nicol, Donghyun Kim
-
Patent number: 9969998Abstract: Provided are variant adenosine deaminase 2 (ADA2) proteins, conjugates thereof and compositions containing the proteins and/or conjugates. Also provided are methods and uses of the ADA2 proteins or conjugates for treating diseases and conditions, such as a tumor or cancer, and in particular any disease or condition associated with elevated adenosine or other associated marker.Type: GrantFiled: April 8, 2016Date of Patent: May 15, 2018Assignee: Halozyme, Inc.Inventors: Christopher D. Thanos, Lin Wang, H. Michael Shepard